ZA996622B - Treatment of BPH with cGMP elevators. - Google Patents

Treatment of BPH with cGMP elevators.

Info

Publication number
ZA996622B
ZA996622B ZA9906622A ZA996622A ZA996622B ZA 996622 B ZA996622 B ZA 996622B ZA 9906622 A ZA9906622 A ZA 9906622A ZA 996622 A ZA996622 A ZA 996622A ZA 996622 B ZA996622 B ZA 996622B
Authority
ZA
South Africa
Prior art keywords
bph
treatment
cgmp elevators
cgmp
elevators
Prior art date
Application number
ZA9906622A
Other languages
English (en)
Inventor
Michael Grant Wyllie
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Publication of ZA996622B publication Critical patent/ZA996622B/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Urology & Nephrology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
ZA9906622A 1998-10-21 1999-10-20 Treatment of BPH with cGMP elevators. ZA996622B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US10509798P 1998-10-21 1998-10-21

Publications (1)

Publication Number Publication Date
ZA996622B true ZA996622B (en) 2001-04-20

Family

ID=22304008

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA9906622A ZA996622B (en) 1998-10-21 1999-10-20 Treatment of BPH with cGMP elevators.

Country Status (11)

Country Link
EP (1) EP1020190A3 (hu)
JP (1) JP2000128804A (hu)
KR (1) KR20000029222A (hu)
AR (1) AR020850A1 (hu)
AU (1) AU5597799A (hu)
CA (1) CA2287122A1 (hu)
CO (1) CO5150210A1 (hu)
HU (1) HUP9903732A3 (hu)
IL (1) IL132406A0 (hu)
PE (1) PE20001282A1 (hu)
ZA (1) ZA996622B (hu)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW536402B (en) 1998-06-26 2003-06-11 Yamanouchi Pharma Co Ltd Pharmaceutical composition for the therapy of voiding dysfunction
EP1219609B1 (en) 1999-09-16 2007-04-04 Tanabe Seiyaku Co., Ltd. Aromatic nitrogenous six-membered ring compounds
TWI265925B (en) 1999-10-11 2006-11-11 Pfizer Pyrazolo[4,3-d]pyrimidin-7-ones useful in inhibiting type 5 cyclic guanosine 3',5'-monophosphate phosphodiesterases(cGMP PDE5), process and intermediates for their preparation, their uses and composition comprising them
US7273868B2 (en) 2000-04-28 2007-09-25 Tanabe Seiyaku Co., Ltd. Pyrazine derivatives
CN1440393A (zh) 2000-04-28 2003-09-03 田边制药株式会社 环状化合物
IT1318674B1 (it) * 2000-08-08 2003-08-27 Nicox Sa Faramaci per l'incontinenza.
JP2001288115A (ja) * 2001-02-07 2001-10-16 Yamanouchi Pharmaceut Co Ltd 下部尿路症治療剤
EP1364659B1 (en) 2001-02-08 2009-11-11 Ono Pharmaceutical Co., Ltd. Remedies for urinary diseases comprising lpa receptor controlling agents
KR100540623B1 (ko) 2001-02-26 2006-01-11 다나베 세이야꾸 가부시키가이샤 피리도피리미딘 또는 나프틸리딘 유도체
DE10135815A1 (de) * 2001-07-23 2003-02-06 Bayer Ag Verwendung von 2-Alkoxyphenyl-substituierten Imidazotriazinonen
BRPI0616633A2 (pt) * 2005-09-29 2011-06-28 Bayer Healthcare Ag inibidores de pde e combinações dos mesmos para o tratamento de transtornos urológicos
WO2007047282A1 (en) * 2005-10-12 2007-04-26 Lilly Icos Llc Treatment of benign prostatic hypertrophy and lower urinary tract symptoms
RU2008120332A (ru) * 2005-12-20 2010-01-27 Пфайзер Продактс Инк. (Us) Фармацевтическая композиция для лечения luts, содержащая ингибитор pde5 и мускариновый антагонист
US20100210668A1 (en) * 2007-10-02 2010-08-19 Dong-A Pharm. Co., Ltd. Composition and method for treatment or prevention of benign prostatic hyperplasia and lower urinary tract symptoms
KR20110062943A (ko) * 2009-12-04 2011-06-10 주식회사종근당 퀴나졸린 유도체를 유효성분으로 하는 전립선 비대증 예방 또는 치료제
CN108949717B (zh) 2012-05-11 2023-06-20 珍白斯凯尔有限公司 抗炎性肽及包含其的组合物
WO2013169060A1 (ko) 2012-05-11 2013-11-14 주식회사 카엘젬백스 패혈증 예방 또는 치료용 조성물
US10967000B2 (en) 2012-07-11 2021-04-06 Gemvax & Kael Co., Ltd. Cell-penetrating peptide, conjugate comprising same and composition comprising same
ES2716870T3 (es) 2013-04-19 2019-06-17 Gemvax & Kael Co Ltd Composición para el tratamiento y prevención de lesión isquémica
CA2912557A1 (en) 2013-06-07 2014-12-11 Gemvax & Kael Co., Ltd. Biological markers useful in cancer immunotherapy
KR102166545B1 (ko) 2013-06-21 2020-10-16 주식회사 젬백스앤카엘 호르몬 분비 조절제, 이를 포함하는 조성물, 및 이를 사용한 호르몬 분비 조절 방법
KR101691479B1 (ko) 2013-10-23 2017-01-02 주식회사 젬백스앤카엘 전립선 비대증 치료 및 예방용 조성물
KR102494803B1 (ko) 2013-11-22 2023-02-06 주식회사 젬백스앤카엘 혈관 신생 억제 활성을 가지는 펩티드 및 이를 포함하는 조성물
ES2809251T3 (es) 2013-12-17 2021-03-03 Gemvax & Kael Co Ltd Composición para tratar cáncer de próstata
CN106456697B (zh) 2014-04-11 2019-12-17 珍白斯凯尔有限公司 具有纤维化抑制活性的肽和含有其的组合物
ES2962532T3 (es) 2014-04-30 2024-03-19 Gemvax & Kael Co Ltd Composición para el trasplante de órganos, tejidos o células, kit y procedimiento de trasplante
KR102413243B1 (ko) 2014-12-23 2022-06-27 주식회사 젬백스앤카엘 안질환 치료 펩티드 및 이를 포함하는 안질환 치료용 조성물
EP3263122B1 (en) 2015-02-27 2020-05-06 Gemvax & Kael Co., Ltd. Peptide for preventing hearing loss, and composition comprising same
US11015179B2 (en) 2015-07-02 2021-05-25 Gemvax & Kael Co., Ltd. Peptide having anti-viral effect and composition containing same
EP3441082B1 (en) 2016-04-07 2023-06-21 Gemvax & Kael Co., Ltd. Peptide having effects of increasing telomerase activity and extending telomere, and composition containing same

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9114760D0 (en) * 1991-07-09 1991-08-28 Pfizer Ltd Therapeutic agents
GB9401090D0 (en) * 1994-01-21 1994-03-16 Glaxo Lab Sa Chemical compounds
DE19540642A1 (de) * 1995-11-01 1997-05-07 Stief Christian Georg Priv Doz Verwendung von Inhibitoren der Phosphodiesterase bei der Behandlung von Prostataerkrankungen
DE19642322A1 (de) * 1996-10-14 1998-04-16 Bayer Ag Neue 3-Heterocyclyl-substituierte Pyrazolderivate
DE19709126A1 (de) * 1997-03-06 1998-09-10 Bayer Ag Arylamin-, -oxy-, -thio-substituierte Dihydropurinone und Pyrazolopyrimidine
WO1999002161A1 (en) * 1997-07-09 1999-01-21 Forssmann Wolf Georg Use of phosphordiesterase inhibitors in the treatment of prostatic diseases

Also Published As

Publication number Publication date
EP1020190A2 (en) 2000-07-19
PE20001282A1 (es) 2000-11-18
JP2000128804A (ja) 2000-05-09
EP1020190A3 (en) 2000-10-25
AU5597799A (en) 2000-05-04
HUP9903732A3 (en) 2002-01-28
HUP9903732A2 (hu) 2000-08-28
IL132406A0 (en) 2001-03-19
AR020850A1 (es) 2002-05-29
CA2287122A1 (en) 2000-04-21
HU9903732D0 (en) 1999-12-28
KR20000029222A (ko) 2000-05-25
CO5150210A1 (es) 2002-04-29

Similar Documents

Publication Publication Date Title
ZA996622B (en) Treatment of BPH with cGMP elevators.
ZA981842B (en) Treated horticultural substrates.
ZA200000411B (en) Machine-room-less elevator.
HK1054389A1 (en) Quinoline and quinazoline compounds useful in therapy, particularly in the treatment of begnin prostatic hyperplasia.
ZA200007642B (en) Treatment of airborne microorganisms.
ZA978918B (en) Metal surface treatment.
ZA200202822B (en) Oncolytic combinations for the treatment of cancer.
ZA97986B (en) Treatment of liquors.
HUP0104543A3 (en) Lime treatment
ZA978640B (en) Use of 1-hydroxy-2-pyridones for the treatment of saborrheic dermatitis.
GB9815312D0 (en) Biomas treatment
ZA973843B (en) Treatment of asthma with TNFR-lg.
SG68707A1 (en) Tank treatment assembly
ZA991144B (en) Treatment of iron chloride.
GB9800954D0 (en) Well treatment with micro-organisms
ZA200203166B (en) Treatment of cancer.
ZA99253B (en) Treatment of waxes.
AU2002256967A1 (en) Treating or reducing the risk of cardiovascular disease
ZA200007396B (en) Method of treatment.
GB9715222D0 (en) Bath lift
AP2004002980A0 (en) The treatment of lipodystrophy.
GB0102866D0 (en) Bath lift
GB9820844D0 (en) Bath lifts
GB9818524D0 (en) Inorgasmia treatment
GB9815497D0 (en) Treatment